Baker SD - Search Results

1

Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.

Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD. Zimmerman EI, et al. Among authors: baker sd. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. doi: 10.1158/1078-0432.CCR-12-3306. Epub 2013 Jan 22. Clin Cancer Res. 2013. PMID: 23340295 Free PMC article.

2

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Sparreboom A, et al. Among authors: baker sd. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):183-90. doi: 10.1016/s1570-0232(02)00167-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12031845

3

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Among authors: baker sd. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

4

Distribution of paclitaxel in plasma and cerebrospinal fluid.

Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: baker sd. Anticancer Drugs. 2003 Jun;14(5):365-8. doi: 10.1097/00001813-200306000-00007. Anticancer Drugs. 2003. PMID: 12782943 Clinical Trial.

5

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: baker sd. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

6

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: baker sd. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

7

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Baker SD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1976-83. doi: 10.1158/1078-0432.ccr-0842-03. Clin Cancer Res. 2004. PMID: 15041715 Clinical Trial.

8

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Engels FK, et al. Among authors: baker sd. Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001. Clin Pharmacol Ther. 2004. PMID: 15116057 Clinical Trial.

9

Determination of fraction unbound docetaxel using microequilibrium dialysis.

Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A. Acharya MR, et al. Among authors: baker sd. Anal Biochem. 2004 Aug 1;331(1):192-4. doi: 10.1016/j.ab.2004.03.045. Anal Biochem. 2004. PMID: 15246014 No abstract available.

10

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Baker SD, et al. Clin Cancer Res. 2004 Dec 15;10(24):8341-50. doi: 10.1158/1078-0432.CCR-04-1371. Clin Cancer Res. 2004. PMID: 15623611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters